Dr. Rimawi Discusses the Clinical Need for Immunotherapy in HER2-Positive Breast Cancer
Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.
Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the clinical need for immunotherapy regimens for patients with HER2-positive breast cancer.
According to Rimawi, there has been a robust interest in the immune system in patients with breast cancer, explains Rimawi. Trastuzumab (Herceptin) has immune effects in patients with HER2-positive breast cancer creating a role for immunotherapy in this subset. There are agents in many settings that are being investigated in combination, says Rimawi, which will hopefully benefit more patients with breast cancer.
